BLASOLUTIONINJECTION
Approved
Feb 2025
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
IRA Negotiated
MERILOG (insulin aspart-szjj) by Sanofi is insulin, including insulin aspart products is the regulation of glucose metabolism. Approved for diabetes mellitus, type 1, diabetes mellitus, type 2, diabetes. First approved in 2025.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MERILOG (insulin aspart-SZJJ) is a rapid-acting insulin analog approved by FDA on February 14, 2025, for treatment of Type 1 and Type 2 diabetes mellitus. It works by stimulating peripheral glucose uptake in skeletal muscle and fat while inhibiting hepatic glucose production, thereby lowering blood glucose levels. The drug is administered as a subcutaneous injection solution.
Growth
Early-stage growth product with significant price compression via IRA negotiation; team building and market access strategy will be critical focuses.
Mechanism of Action
insulin, including insulin aspart products is the regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis,…
Pharmacologic Class:
Insulin Analog
Indications (3)
Worked on MERILOG at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.